[EN] SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS [FR] DÉRIVÉS DE SULPHAMOYLARYLE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT DE LA FIBROSE HÉPATIQUE
Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis
申请人:Janssen Pharmaceutica NV
公开号:US10654837B2
公开(公告)日:2020-05-19
Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them, alone or in combination with other drugs, in fibrosis and/or cirrhosis prevention or therapy.
SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS
申请人:Janssen Pharmaceutica NV
公开号:US20190345145A1
公开(公告)日:2019-11-14
Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them, alone or in combination with other drugs, in fibrosis and/or cirrhosis prevention or therapy.
[EN] SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS<br/>[FR] DÉRIVÉS DE SULPHAMOYLARYLE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT DE LA FIBROSE HÉPATIQUE
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2018145620A1
公开(公告)日:2018-08-16
Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them, alone or in combination with other drugs, in fibrosis and/or cirrhosis prevention or therapy.
Trideuteromethylation Enabled by a Sulfoxonium Metathesis Reaction
作者:Zuyuan Shen、Shilei Zhang、Huihui Geng、Jiarui Wang、Xinyu Zhang、Anqi Zhou、Cheng Yao、Xiaobei Chen、Wei Wang
DOI:10.1021/acs.orglett.8b03641
日期:2019.1.18
A conceptually novel sulfoxonium metathesisreaction between TMSOI and cost-effective DMSO-d6 is developed for the efficient generation of a new trideuteromethylation reagent TDMSOI. The new reagent TDMSOI is produced highly efficiently by simply heating a mixture of TMSOI and DMSO-d6 and directly used for subsequent trideuteromethylation in a “one-pot” operation. The preparative power of the new versatile
TMSOI 和经济高效的 DMSO- d 6之间的概念上新颖的硫鎓复分解反应被开发出来,用于有效生成新型三氘代甲基化试剂 TDMSOI。新试剂TDMSOI只需加热TMSOI和DMSO- d 6的混合物即可高效生产,并直接用于后续的“一锅”操作中的三氘代甲基化。新的多功能试剂和“一锅”方案的制备能力通过其以高产率和有用的方式将-CD 3部分安装到广泛的功能中而得到证明,包括苯酚、苯硫酚、酸性胺和烯醇化亚甲基单元。氘化水平 (>87% D)。